The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Quality and Safety Requirements for Sustainable Phage Therapy Products
Open accessAbstract
The worldwide antibiotic crisis has led to a renewed interest in phage therapy. Since time immemorial phages control bacterial populations on Earth. Potent lytic phages against bacterial pathogens can be isolated from the environment or selected from a collection in a matter of days. In addition, phages have the capacity to rapidly overcome bacterial resistances, which will inevitably emerge. To maximally exploit these advantage phages have over conventional drugs such as antibiotics, it is important that sustainable phage products are not submitted to the conventional long medicinal product development and licensing pathway. There is a need for an adapted framework, including realistic production and quality and safety requirements, that allows a timely supplying of phage therapy products for 'personalized therapy' or for public health or medical emergencies. This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, M. H. (1959) · Interscience Publishers eBooks · doi:10.5962/bhl.title.6966 · Cited by 2,097
Tackling antibiotic resistance
Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G. A., Kishony, R., Kreiswirth, B. N., Kutter, E., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2693 · Cited by 1,062
Self-citationWestover, K. M. (1999) · Ecology · doi:10.1890/0012-9658(1999)080[1447:em]2.0.co;2 · Cited by 472
Antibiotic Stress Induces Genetic Transformability in the Human Pathogen Streptococcus pneumoniae
Prudhomme, M., Attaiech, L., Sanchez, G., Martin, B., & Claverys, J.-P. (2006) · Science · doi:10.1126/science.1127912 · Cited by 451
Gene transfer agents: phage-like elements of genetic exchange
Lang, A. S., Zhaxybayeva, O., & Beatty, J. T. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2802 · Cited by 416
Techniques in Microbial Ecology
(1990) · Methods in Microbiology · doi:10.1016/s0580-9517(08)x7011-4 · Cited by 320
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0313-5 · Cited by 298
Self-citationReversing Bacterial Resistance to Antibiotics by Phage-Mediated Delivery of Dominant Sensitive Genes
Edgar, R., Friedman, N., Molshanski-Mor, S., & Qimron, U. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.05741-11 · Cited by 217
Bacteria–Phage Interactions in Natural Environments
Díaz-Muñoz, S. L., & Koskella, B. (2014) · Advances in Applied Microbiology · doi:10.1016/b978-0-12-800259-9.00004-4 · Cited by 191
Hall, A. R., De Vos, D., Friman, V.-P., Pirnay, J.-P., & Buckling, A. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.00757-12 · Cited by 180
Self-citation
Cited by
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Biotechnological applications of bacteriophages: State of the art
Harada, L. K., Silva, E. C., Campos, W. F., Del Fiol, F. S., Vila, M., Dąbrowska, K., Krylov, V. N., & Balcão, V. M. (2018) · Microbiological Research · doi:10.1016/j.micres.2018.04.007 · Cited by 318
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Alessa, O., Aiba, Y., Arbaah, M., Hidaka, Y., Watanabe, S., Miyanaga, K., Wannigama, D. L., & Cui, L. (2025) · Molecules · doi:10.3390/molecules30153132 · Cited by 21
Metadata
- Authors
- Pirnay, J.-P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J. R., Corte-Real, S., Debarbieux, L., Dublanchet, A., De Vos, D., Gabard, J., Garcia, M., Goderdzishvili, M., Górski, A., Hardcastle, J., Huys, I., Kutter, E., Lavigne, R., Merabishvili, M., Olchawa, E., Parikka, K. J., Patey, O., Pouilot, F., Resch, G., Rohde, C., Scheres, J., Skurnik, M., Vaneechoutte, M., Van Parys, L., Verbeken, G., Zizi, M., & Van den Eede, G.
- Venue
- Pharmaceutical Research
- Published
- 2015-01-14
- Volume
- 32
- Issue
- 7
- Pages
- 2173-2179
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1974881706
- Cited by
- 276
- References
- 18
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality and Safety Requirements for Sustainable Phage Therapy Products. https://app.cochat.ai/papers/10.1007/s11095-014-1617-7
- The paper
- Pirnay, J.-P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J. R., Corte-Real, S., Debarbieux, L., Dublanchet, A., De Vos, D., Gabard, J., Garcia, M., Goderdzishvili, M., Górski, A., Hardcastle, J., Huys, I., Kutter, E., Lavigne, R., Merabishvili, M., . . . Van den Eede, G. (2015). Quality and Safety Requirements for Sustainable Phage Therapy Products. Pharmaceutical Research. https://doi.org/10.1007/s11095-014-1617-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.